Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18649045 | 0.85 | BRD4 (0.51) | BRD4MAPK14MAPK8MAPK9MAPK10 | |
| SCHEMBL16651455 | 0.79 | BRD4 (0.73) | BRD4 | |
| SCHEMBL16654877 | 0.78 | BRD4 (0.53) | BRD4MAPK14MAPK8EP300 | |
| SCHEMBL16660698 | 0.78 | BRD4 (0.62) | BRD4MAPK14MAPK8 | |
| SCHEMBL19927971 | 0.77 | BRD4 (0.64) | BRD4MAPK14EP300 | |
| SCHEMBL16651076 | 0.77 | BRD4 (0.72) | BRD4MAPK14MAPK8MAPK9MAPK10 | |
| SCHEMBL16650378 | 0.76 | BRD4 (0.63) | BRD4MAPK14EP300 | |
| SCHEMBL29849018 | 0.76 | BRD4 (0.57) | BRD4EP300 | |
| SCHEMBL16651500 | 0.76 | BRD4 (0.57) | BRD4EP300 | |
| SCHEMBL16650282 | 0.76 | BRD4 (0.75) | BRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK14 2056/4885MAPK8 1913/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD4 5/4885MAPK14 2056/4885MAPK8 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.